BioCentury
ARTICLE | Finance

The market speaks

July 26, 1999 7:00 AM UTC

Genentech's second "IPO" and stellar after-market performance provide the first benchmark of the company's true value since its stock was capped at $82.50 in May 1995. In DNA's second coming, the stock closed the week at $129, up $32 (33 percent), after gaining $30 to $127 on 11.6 million shares traded in its first day of trading on Tuesday (see BioCentury Extra, July 21). ...